Answers are grounded in this paper and cite their sources.
The incidence of lung cancer is high, but the survival rate is low. For operable stage III non-small cell lung cancer, neoadjuvant chemotherapy, chemoradiotherapy or chemotherapy combined with immunotherapy, or postoperative adjuvant therapy can be used. We present neoadjuvant immunotherapy combined with chemotherapy for stage III lung cancer.
No takes yet. Share an insight, caveat, or question.
Ju Zhang (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: